广东省中医院/广州中医药大学第二附属医院,广东省广州市越秀区大德路111号,510120
drlinlin620@163.com
收稿:2021-06-29,
修回:2021-08-25,
纸质出版:2021-11-17
移动端阅览
陈远彬,范斐婷,吴蕾等.培土生金中药联合西医常规疗法治疗慢性阻塞性肺疾病稳定期的Meta分析与GRADE评价[J].中医杂志,2021,62(22):1970-1978.
CHEN Yuanbin,FAN Feiting,WU Lei,et al.“Earth-banking up to Generate Metal” Method in Chinese Herbal Medicine Combined with Conventional Therapy for Stable Chronic Obstructive Pulmonary Disease: Meta Analysis with GRADE Assessment[J].Journal of Traditional Chinese Medicine,2021,62(22):1970-1978.
陈远彬,范斐婷,吴蕾等.培土生金中药联合西医常规疗法治疗慢性阻塞性肺疾病稳定期的Meta分析与GRADE评价[J].中医杂志,2021,62(22):1970-1978. DOI: 10.13288/j.11-2166/r.2021.22.009.
CHEN Yuanbin,FAN Feiting,WU Lei,et al.“Earth-banking up to Generate Metal” Method in Chinese Herbal Medicine Combined with Conventional Therapy for Stable Chronic Obstructive Pulmonary Disease: Meta Analysis with GRADE Assessment[J].Journal of Traditional Chinese Medicine,2021,62(22):1970-1978. DOI: 10.13288/j.11-2166/r.2021.22.009.
目的
2
系统评价培土生金中药联合西医常规疗法治疗慢性阻塞性肺疾病(简称慢阻肺)稳定期的有效性、安全性以及证据质量。
方法
2
检索中国生物医学文献数据库、维普数据库、中国知网、万方数据知识服务平台、Embase和PubMed数据库,收集培土生金中药联合西医常规疗法治疗慢阻肺稳定期的随机、双盲、安慰剂对照试验,检索时间范围为各数据库建库至2021年5月31日。采用Cochrane偏倚风险评估工具评价纳入研究的方法学质量,使用RevMan 5.3软件对结局指标[包括慢性阻塞性肺疾病评估测试(CAT)评分、圣乔治呼吸问卷(SGRQ)评分、急性加重频次、六分钟步行距离(6MWD)、改良版英国医学研究会呼吸困难量表(mMRC)评分、第一秒用力呼气容积(FEV1)、BODE指数和不良事件发生率]进行Meta分析,并参考GRADE标准对证据质量进行汇总和分级。
结果
2
共纳入14项研究,合计2209例患者。Meta分析结果显示:与对照组相比,培土生金中药联合西医常规疗法在减少急性加重频次[
SMD
=-0.76次,95%
CI
(-1.27,-0.25),
P
=0.004]和降低SGRQ评分[
MD
=-4.68分,95%
CI
(-9.14,0.22),
P
=0.04]方面,疗效更为显著,证据质量为中等;并可增加6MWD[
MD
=29.00 m,95%
CI
(6.04,51.96),
P
=0.01],但质量证据较低。培土生金中药联合西医常规疗法对CAT评分、BODE指数、FEV1和mMRC评分的改善并不优于对照组,证据质量为中至极低。
结论
2
培土生金中药联合西医常规疗法治疗慢阻肺稳定期可改善患者的生活质量,并减少急性加重,但在增加运动耐力和安全性评估方面的证据质量低,尚需更多高质量的研究证实并提升证据级别。
To systematically evaluate the effectiveness and safety of Chinese herbal medicine that banks up earth to generate metal (CHM-BUEGM) in combination with conventional therapy for treatment of chronic obstructive pulmonary disease (COPD), and to assess the quality of the evidence.
Methods
2
Electronic databases including SinoMed, VIP, CNKI, Wanfang, Embase and PubMed were searched from the inception dates to May 31st, 2021 for double-blind, placebo-controlled randomized trials that explores CHM-BUEGM in combination with conventional therapy for stable patients with COPD. Cochrane risk of bias tool was used to assess the methodological quality of the included studies; RevMan 5.3 software was used to perform meta analyses of outcomes including COPD assessment test (CAT) score, St George's Respiratory Questionnaire (SGRQ) score, frequency of acute exacerbation, six-minute walking distance (6MWD), modified medical research council (mMRC) score, forced expiratory volume in one second (FEV1), BODE index and incidence of adverse events; the certainty of the evidence was evaluated by GRADE.
Results
2
Fourteen studies involving 2209 participants were included. The results of meta analyses showed that compared to control group, CHM-BUEGM plus conventional therapy was superior in reducing frequency of acute exacerbation (
SMD
: -0.76, 95%
CI
: [-1.27, -0.25],
P
=0.004), lowering SGRQ score (
MD
: -4.68, 95%
CI
: [-9.14, 0.22],
P
=0.04) and increasing 6MWD (
MD
: 29.00, 95%
CI
: [6.04, 51.96],
P
=0.01). CHM-BUEGM in combination with conventional therapy was not superior to control group in improving CAT score, BODE index, FEV1 and mMRC score with moderate to very low certainty of evidence.
Conclusion
2
CHM-BUEGM combined with conventional therapy can improve the quality of life and reduce acute exacerbation of patients with stable COPD, but the certainty of evidence on increasing exercise endurance and safety is low, which needs more high-quality studies for confirmation and improve level of evidence.
MATHERS CD , LONCAR D . Projections of global mortality and burden of disease from 2002 to 2030 [J]. PLoS Med , 2006 , 3 ( 11 ): e442 .
FANG L , GAO P , BAO H , et al . Chronic obstructive pulmonary disease in China: a nationwide prevalence study [J]. Lancet Respir Med , 2018 , 6 ( 6 ): 421 - 430 .
Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis , management, and prevention of chronic obstructive pulmonary disease[EB/OL].( 2017-12-09 )[ 2021-05-31 ]. https://gold copd.org/gold- reports/ https://goldcopd.org/gold-reports/ .
QASEEM A , WILT TJ , WEINBERGER SE , et a1 . Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society [J]. Ann Intern Med , 2011 , 155 ( 3 ) : 179 - 191 .
中华医学会呼吸病学分会慢性阻塞性肺疾病学组 . 慢性阻塞性肺疾病诊治指南(2007年修订版) [J]. 中华结核和呼吸杂志 , 2007 , 30 ( 1 ): 8 - 17 .
中华医学会呼吸病学分会慢性阻塞性肺疾病学组 . 慢性阻塞性肺疾病诊治指南(2013年修订版) [J]. 中华结核和呼吸杂志 , 2013 , 36 ( 4 ): 255 - 264 .
HIGGINS JPT , GREEN S . Cochrane handbook for systematic reviews of interventions Version 5 . 3 . 3 (updated 2016 )[EB/OL].( 2016-5-30 )[ 2020-12-20 ]. http:// training.cochrane.org/handbook http://training.cochrane.org/handbook .
GUYATT GH , OXMAN AD , VIST GE , et al . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations [J]. BMJ , 2008 , 336 ( 7650 ): 924 - 926 .
何迎春 , 陈海玲 , 张如富 . 补中益气汤加减改善慢性阻塞性肺病稳定期患者生活质量的临床疗效观察 [J]. 中华中医药学刊 , 2010 , 28 ( 3 ): 506 - 507 .
吴蕾 , 林琳 , 许银姬 , 等 . 健脾益肺Ⅱ号治疗慢性阻塞性肺疾病稳定期178例临床研究 [J]. 中医杂志 , 2011 , 52 ( 17 ): 1465 - 1468 .
杨珺超 , 王真 , 楼雅芳 , 等 . 益气健脾颗粒剂联合西药治疗慢性阻塞性肺疾病稳定期肺脾气虚型60例临床观察 [J]. 中医杂志 , 2013 , 54 ( 22 ): 1933 - 1936 .
章潜 , 王真 . 益气健脾颗粒对COPD稳定期患者肺功能指标的影响 [J]. 浙江中医药大学学报 , 2014 , 38 ( 5 ): 575 - 577 .
杨珺超 , 王真 , 徐俭朴 , 等 . 益气健脾法对144例慢性阻塞性肺疾病稳定期肺脾气虚型患者生活质量的影响 [J]. 中华中医药杂志 , 2014 , 29 ( 2 ): 638 - 640 .
GUO SJ , SUN ZT , LIU ES , et al . Effect of Bufei granule on stable chronic obstructive pulmonary disease: a randomized, double blinded, placebo-controlled, and multicenter clinical study [J]. J Tradit Chin Med , 2014 , 34 ( 4 ): 437 - 444 .
李乔 , 卢家胜 , 班文明 , 等 . 自拟补肺合剂对COPD稳定期患者肺功能的影响 [J]. 中医药临床杂志 , 2016 , 28 ( 7 ): 962 - 965 .
LI FS , ZHANG YL , LI Z , et al . Randomized, double-blind, placebo-controlled superiority trial of the Yiqigubiao pill for the treatment of patients with chronic obstructive pulmonary disease at a stable stage [J]. Exp Ther Med , 2016 , 12 ( 4 ) : 2477 - 2488 .
金晶 , 王晶 , 姚梓平 , 等 . 益气固表丸对COPD稳定期患者Th17/Treg平衡的影响 [J]. 新疆医科大学学报 , 2018 , 41 ( 9 ): 1182 - 1185 .
HONG M , HONG C , CHEN H , et al . Effects of the Chinese herb formula Yufeining on stable chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial [J]. Medicine(Balt) , 2018 , 97 ( 39 ) : e12461 .
MA J , ZHENG J , ZHONG N , et al . Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study [J]. Int J Chron Obstruct Pulmon Dis , 2018 , 13 : 3107 - 3114 . doi: 10. 2147/COPD.S170555 http://dx.doi.org/10.2147/COPD.S170555 .
SHERGIS JL , THIEN F , WORSNOP CJ , et al . 12-month randomised controlled trial of ginseng extract for moderate COPD [J]. Thorax , 2019 , 74 ( 6 ) : 539 - 545 .
CHEN Y , LIN L , WU L , et al . Effect of Panax Ginseng (G115) capsules versus placebo on acute exacerbations in patients with moderate to very severe COPD: a randomized controlled trial [J]. Int J Chron Obstruct Pulmon Dis , 2020 , 15 : 671 - 680 . doi: 10.2147/COPD.S236425 http://dx.doi.org/10.2147/COPD.S236425 .
陈远彬 . 培土生金法治疗慢性阻塞性肺疾病的证据评价和多中心随机对照临床研究 [D]. 广州 : 广州中医药大学 , 2020 .
CHEN X , MAY B , DI YM , et al . Oral Chinese herbal medicine combined with pharmacotherapy for stable COPD: a systematic review of ef fect on BODE index and six minute walk test [J]. PLoS One , 2014 , 9 ( 3 ): e91830 .
AN X , ZHANG AL , MAY BH , et al . Oral Chinese herbal medicine for improvement of quality of life in patients with stable chronic obstr uctive pulmonary disease: a systematic review [J]. J Altern Complement Med , 2012 , 18 ( 8 ): 731 - 743 .
欧雅丽 , 许坚 . 培土生金法治疗COPD临床研究的系统评价 [J]. 世界科学技术-中医药现代化 , 2015 , 17 ( 12 ): 2632 - 2639 .
王益斐 , 郦岳 , 周杨 , 等 . 培土生金法治疗慢性阻塞性肺疾病临床疗效的Meta分析 [J]. 中国中医急症 , 2017 , 26 ( 11 ): 1899 - 1902,1910 .
李航 , 黄慧婷 , 詹少锋 , 等 . 培土生金法治疗慢性阻塞性肺疾病稳定期疗效的Meta分析 [J]. 广州中医药大学学报 , 2017 , 34 ( 1 ): 132 - 139 .
CHENG CW , WU TX , SHANG HC , et al . CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration (traditional Chinese version) [J]. Ann Intern Med , 2017 , 167 ( 2 ): W7 - W20 .
0
浏览量
3
下载量
5
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号